Assessment Of Financial Well Being And Financial Capability In Patients Of Cirrhosis With Minimal Hepatic Encephalopathy And Response To Rifaximin Therapy : A Double Blind Randomized Controlled Trial

Assessment Of Financial Well Being And Financial Capability In Patients Of Cirrhosis With Minimal Hepatic Encephalopathy And Response To Rifaximin Therapy : A Double Blind Randomized Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106253

Enrollment

118

Registered

2026-03-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K721- Chronic hepatic failure

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Rifaximin: Tab rifaximin 55o mg bd will be given to one group for 6 months along with standard of care Control Intervention1: placebo: mu

Eligibility

Inclusion criteria

Inclusion criteria: all consecutive patients of cirrhosis presenting to outpatient and in patient of hospital

Exclusion criteria

Exclusion criteria: overt he creat more than 1.5 patients with hepatocellular carcinoma active ongoing infection , upper gastrointestinal bleed in last 6 weeks alcohol last 3 months pregnant patients , Patient on sedatives /anticonvulsants/ anti psychiatry drugs Patient who received rifaximin/ lactulose/ probiotics/ LOLA/ antibiotics in last 1 month Neurological and psychiatric illness

Design outcomes

Primary

Measure	Time frame
To evaluate Financial Well Being and Financial Capability in patients of Cirrhosis with MHE. To evaluate change in Financial Well Being and Capability in patients of Cirrhosis with MHE after rifaximin therapy Timepoint: after 6 months of randomisation	—

Secondary

Measure	Time frame
To evaluate the relationship between improvement in MHE and changes in Financial Capability and Financial Well being in patients of Cirrhosis with MHE To evaluate for complications at 3 and 6 months. To evaluate change in Health-Related Quality of Life after 6 months of Rifaximin therapy in patients of Cirrhosis with MHE Timepoint: after 6 months of randomisation	—

Countries

India

Contacts

Public ContactDr Nitin rustogi

ABVIMS and RML Hospital New delhi

drvaishali22.db@gmail.com8376022402

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026